Supporting AML World Awareness Day 2026
Acute myeloid leukemia (AML) is one of the most aggressive forms of bloodcancer. It progresses rapidly, and end even after treatment, the fight is often not over. The real challenge? Minimal Residual Disease (MRD) -> These are the therapy-resistant leukemia cells that remain hidden in the bone marrow after treatment. They are undetectable with standard tests, yet they are the leading cause of relapse, months or even years later.
MRD does not act alone -> The surrounding bone marrow environment protects and sustains these cells, making them even harder to eliminate. Despite its critical role, our understanding of MRD persistence and relapse remains limited, slowing the development of effective therapies and impacting patient survival.
This is we hope to contribute, we are tackling one of the biggest unmet needs in leukemia care by:
- bringing together 23 academic/non-academic partners and 10 doctoral candidates
- and by conducting 10 research projects to investigae how MRD survives and drives relapse.
Our mission is clear: Improve survival outcomes and bring us closer to truly curative therapies for AML patients.
MIRACLE-Leukemia is a MSCA doctoral network and aims to combat MRD to improve leukemia treatment. MIRACLE-stands for "Integrated multi-angle research and training network to eradicate leukemia minimal residual disease. MSCA means ‘Marie Skłodowska-Curie Actions’, a European programme that funds and trains young researchers to work together across countries and find new solutions to health and science challenges.
